[go: up one dir, main page]

DE69112917D1 - Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse. - Google Patents

Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.

Info

Publication number
DE69112917D1
DE69112917D1 DE69112917T DE69112917T DE69112917D1 DE 69112917 D1 DE69112917 D1 DE 69112917D1 DE 69112917 T DE69112917 T DE 69112917T DE 69112917 T DE69112917 T DE 69112917T DE 69112917 D1 DE69112917 D1 DE 69112917D1
Authority
DE
Germany
Prior art keywords
improve
size
crystal structure
crystallization process
crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69112917T
Other languages
English (en)
Other versions
DE69112917T2 (de
Inventor
Michael Midler
Paul D Liu
Edward L Paul
Mauricio Futran
Edwin F Whittington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69112917(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69112917D1 publication Critical patent/DE69112917D1/de
Application granted granted Critical
Publication of DE69112917T2 publication Critical patent/DE69112917T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/0004Crystallisation cooling by heat exchange
    • B01D9/0009Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D9/00Crystallisation
    • B01D9/0018Evaporation of components of the mixture to be separated
    • B01D9/0027Evaporation of components of the mixture to be separated by means of conveying fluid, e.g. spray-crystallisation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/20Jet mixers, i.e. mixers using high-speed fluid streams
    • B01F25/23Mixing by intersecting jets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30Micromixers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00Fluid handling
    • Y10T137/8593Systems
    • Y10T137/87571Multiple inlet with single outlet
    • Y10T137/87652With means to promote mixing or combining of plural fluids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE69112917T 1990-06-15 1991-06-14 Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse. Expired - Fee Related DE69112917T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53861190A 1990-06-15 1990-06-15
US70668291A 1991-06-03 1991-06-03

Publications (2)

Publication Number Publication Date
DE69112917D1 true DE69112917D1 (de) 1995-10-19
DE69112917T2 DE69112917T2 (de) 1996-05-15

Family

ID=27065873

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69112917T Expired - Fee Related DE69112917T2 (de) 1990-06-15 1991-06-14 Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.

Country Status (7)

Country Link
US (1) US5314506A (de)
EP (1) EP0461930B1 (de)
JP (1) JP3282731B2 (de)
CA (1) CA2044706C (de)
DE (1) DE69112917T2 (de)
ES (1) ES2078447T3 (de)
IE (1) IE67187B1 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007582A1 (en) * 1992-10-06 1994-04-14 Merck & Co., Inc. Dual jet crystallizer apparatus
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
KR100279170B1 (ko) * 1993-12-09 2001-01-15 나루세 스스무 알루미나를 제조하는 방법 및 장치
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5891526A (en) * 1995-12-01 1999-04-06 International Business Machines Corporation Apparatus for mixing a multi-component encapsulant and injecting it through a heated nozzle onto a part to be encapsulated
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
GB9702886D0 (en) * 1996-09-28 1997-04-02 Agglomeration Technology Ltd Spray crystallised products and processes
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20020151729A1 (en) * 1997-02-26 2002-10-17 Cheng Wen J. Novel process for the preparation of form 1 ranitidine hydrochloride
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
US6467947B1 (en) * 1997-08-19 2002-10-22 Commonwealth Scientific And Industrial Research Organisation Method and apparatus for mixing
GB2341120B (en) 1998-09-04 2002-04-17 Aea Technology Plc Controlling uniformity of crystalline precipitates
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
JP3862957B2 (ja) * 1999-01-29 2006-12-27 ブリストル−マイヤーズ スクイブ カンパニー 音波衝突ジェット結晶化装置及び方法
US6234664B1 (en) 1999-02-26 2001-05-22 Microtrac, Inc. Mixing reservoir for an automated recirculating particle size analysis system
GB9905512D0 (en) * 1999-03-10 1999-05-05 Smithkline Beecham Plc Process
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6546359B1 (en) 2000-04-24 2003-04-08 Sun Microsystems, Inc. Method and apparatus for multiplexing hardware performance indicators
TWI236930B (en) * 2000-05-26 2005-08-01 Pfizer Prod Inc Reactive crystallization method to improve particle size
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
AU2001288724A1 (en) * 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
DE60117873T2 (de) * 2000-12-22 2006-08-24 Baxter International Inc., Deerfield Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
BR0211028A (pt) * 2001-06-22 2004-06-15 Pfizer Prod Inc Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
AU2002317409B2 (en) * 2001-08-06 2007-06-21 Astrazeneca Ab Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (MCT)
CA2458889C (en) * 2001-08-29 2011-06-21 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
EP1992335A1 (de) 2001-11-01 2008-11-19 Nektar Therapeutics Sprühtrocknungsverfahren und Zusammensetzungen dafür
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
EP1539319A4 (de) * 2002-04-29 2005-10-12 Bristol Myers Squibb Co Zerstäubung verwendendes kristallisationssystem
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
MXPA04011064A (es) * 2002-05-10 2005-02-14 Squibb Bristol Myers Co Sistema de cristalizacion que usa homogenizacion.
US20030227820A1 (en) * 2002-06-05 2003-12-11 Parrent Kenneth Gaylord Apparatus for mixing, combining or dissolving fluids or fluidized components in each other
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
ES2206065B1 (es) 2002-10-31 2005-08-16 Ragactives, S.L. Procedimiento para la obtencion de la forma polimorfica i de finasterida.
US20040185110A1 (en) * 2002-11-08 2004-09-23 Ronald Harland Formulations of low solubility bioactive agents and processes for making the same
US20040098839A1 (en) * 2002-11-27 2004-05-27 Pfizer Inc. Crystallization method and apparatus using an impinging plate assembly
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2003302329B2 (en) 2002-12-30 2010-01-07 Novartis Ag Prefilming atomizer
GB0300339D0 (en) * 2003-01-08 2003-02-05 Bradford Particle Design Ltd Particle formation
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
TW200417371A (en) * 2003-02-21 2004-09-16 Upjohn Co A continuous process for the production of R-rofleponide
US7041144B2 (en) * 2003-03-04 2006-05-09 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization process
US20080194868A1 (en) * 2003-03-04 2008-08-14 Kozyuk Oleg V Hydrodynamic cavitation crystallization device and process
ATE435059T1 (de) * 2003-03-04 2009-07-15 Five Star Technologies Inc Verfahren zur kristallisation unter verwendung von hydrodynamischer kavitation
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
JP4652229B2 (ja) * 2003-03-27 2011-03-16 三井化学株式会社 ビスフェノールaの製造方法
MXPA05011343A (es) 2003-05-08 2005-12-12 Nektar Therapeutics Uk Ltd Materiales particulados.
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1641779A1 (de) * 2003-06-18 2006-04-05 AstraZeneca AB 2-substituierte 5, 6-diaryl-pyrazinderivative als cb1 modulator
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
ITTO20030474A1 (it) * 2003-06-23 2004-12-24 Rotta Res Lab Spa Ora Rottapharm Spa Procedimento per la preparazione di dexloxiglumide
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
ES2315721T5 (es) 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
PL1613598T3 (pl) * 2003-12-16 2012-03-30 Teva Pharma Sposób wytwarzania krystalicznych form aripiprazolu
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
EP1730516A1 (de) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Verfahren und vorrichtung zur bewertung pharmazeutischer zusammensetzungen
HUE028811T2 (en) * 2004-04-01 2017-01-30 Zoetis Services Llc Crystalline pyrazole derivative
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
US7396932B2 (en) * 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7314516B2 (en) * 2004-12-29 2008-01-01 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization device and process
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
EP2279727A3 (de) * 2005-09-15 2011-10-05 Elan Pharma International Limited Nanoteilchenförmige Aripiprazolformulierungen
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
EP1954245A2 (de) * 2005-11-15 2008-08-13 Baxter International Inc. Zusammensetzungen aus lipoxygenase-hemmern
US20090111997A1 (en) * 2005-11-23 2009-04-30 Aaron Cote Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals
TW200800202A (en) * 2005-12-22 2008-01-01 Teva Pharma Processes for reducing particle size of aripiprazole
WO2007086735A1 (en) * 2006-01-26 2007-08-02 Fujifilm Manufacturing Europe B.V. Method for the precipitation of organic compounds
CA2642504A1 (en) * 2006-03-14 2007-09-20 Brian K. Johnson Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
US20070218141A1 (en) * 2006-03-15 2007-09-20 Ashis Kumar Mehta Simvastatin compositions
TWI394753B (zh) 2006-03-17 2013-05-01 Otsuka Pharma Co Ltd 新穎替妥牟拉(tetomilast)晶體
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
EP2012753A2 (de) * 2006-04-28 2009-01-14 Schering Corporation Verfahren zur ausscheidung und isolierung von 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexan-amid-verbindungen durch kontrollierte ausscheidung und pharmazeutische formulierungen damit
WO2008035028A1 (en) * 2006-09-19 2008-03-27 Fujifilm Manufacturing Europe B.V. Preparation of fine particles
EA200970368A1 (ru) * 2006-10-10 2009-10-30 Янссен Фармацевтика Нв Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc DHE is a therapeutic method of administration for the rapid relief of migraine while minimizing side effects
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2008149192A2 (en) * 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2178518A2 (de) * 2007-07-13 2010-04-28 Bend Research, Inc Nanopartikel mit ionisierbaren und schwach wasserlöslichen zellulose-polymeren
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
MX2010001311A (es) * 2007-07-31 2010-04-21 Otsuka Pharma Co Ltd Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US8187554B2 (en) 2008-04-23 2012-05-29 Microfluidics International Corporation Apparatus and methods for nanoparticle generation and process intensification of transport and reaction systems
EP2273978A1 (de) * 2008-04-23 2011-01-19 Merck Sharp & Dohme Corp. Nanopartikelbildung mittels rascher ausfällung
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
AU2010261509A1 (en) * 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
JP5965319B2 (ja) 2009-10-22 2016-08-03 エイピーアイ・ジェネシス,エルエルシー フラボノイド含有組成物の製造方法及び使用
PL2550092T3 (pl) 2010-03-22 2019-01-31 Instillo Gmbh Sposób wytwarzania mikro- lub nanocząstek
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) * 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012050858A1 (en) 2010-09-28 2012-04-19 Dow Global Technologies Llc Reactive flow static mixer with cross-flow obstructions
US10350556B2 (en) 2011-01-07 2019-07-16 Microfluidics International Corporation Low holdup volume mixing chamber
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
US9199209B2 (en) 2011-04-13 2015-12-01 Microfluidics International Corporation Interaction chamber with flow inlet optimization
US9079140B2 (en) 2011-04-13 2015-07-14 Microfluidics International Corporation Compact interaction chamber with multiple cross micro impinging jets
WO2013041944A1 (en) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of micronized candesartan cilexetil
US9732068B1 (en) 2013-03-15 2017-08-15 GenSyn Technologies, Inc. System for crystalizing chemical compounds and methodologies for utilizing the same
CN103551100B (zh) * 2013-10-31 2015-10-28 华南理工大学 一种连续快速反应结晶提高晶体稳定性的装置及方法
US9993436B2 (en) 2014-12-12 2018-06-12 New Jersey Institute Of Technology Porous hollow fiber anti-solvent crystallization-based continuous method of polymer coating on submicron and nanoparticles
EP3294724A4 (de) * 2015-05-08 2018-11-21 Davuluri, Ramamohan Rao Verbessertes verfahren zur herstellung von aripiprazol mit verringerter partikelgrösse
EP3518672A4 (de) 2016-09-29 2020-05-06 JRX Biotechnology, Inc. Verfahren und zusammensetzungen zur modifizierung des pflanzenwachstums und zur reduzierung des wasserverbrauchs von pflanzen
JP6442715B2 (ja) * 2017-04-28 2018-12-26 エム・テクニック株式会社 微粒子の製造方法
CN107551599B (zh) * 2017-10-24 2019-10-22 东南大学 多段进料式反溶剂喷射结晶器及其喷射结晶方法
BR112020019592A2 (pt) 2018-03-28 2021-01-05 Jrx Biotechnology, Inc. Composições agrícolas
JP7320852B2 (ja) 2018-06-22 2023-08-04 デルファイ サイエンティフィック、エルエルシー ナノ材料及び高純度化学物質を連続製造する装置、システム、及び方法
WO2020205539A1 (en) 2019-03-29 2020-10-08 Vizuri Health Sciences Consumer Healthcare, Inc. Compositions and methods for the prevention and treatment of radiation dermatitis, eczema, burns, wounds and certain cancers
CN114262316A (zh) * 2021-12-24 2022-04-01 嘉应学院 纳米橙皮素、其制备方法及所用双匀浆空化射流系统
CN115253367B (zh) * 2022-08-31 2024-07-09 浙江新和成股份有限公司 一种布洛芬微晶的生产装置及结晶方法和产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751335A (en) * 1951-02-01 1956-06-19 Exxon Research Engineering Co Method and apparatus for mixing and contacting fluids
US3622496A (en) * 1969-12-04 1971-11-23 Exxon Research Engineering Co Low-pour dewaxing process utilizing dual solvents
DE3126854C2 (de) 1981-07-08 1984-09-27 Nukem Gmbh, 6450 Hanau Verfahren und Vorrichtung zur Herstellung kugelförmiger Teilchen aus spontan reagierenden flüssigen Komponenten
DE3569201D1 (en) * 1984-03-30 1989-05-11 Kawasaki Steel Co Crystallization apparatus for metal stripping
US4567912A (en) * 1984-07-30 1986-02-04 Acheson Industries, Inc. Multiple spray nozzles
US4663433A (en) * 1985-12-23 1987-05-05 General Electric Company Separation of cyclic oligomeric carbonate from high molecular weight polycarbonate
JPS62289257A (ja) * 1986-06-09 1987-12-16 Ikeuchi:Kk 超微霧噴射ノズル
US4915302A (en) * 1988-03-30 1990-04-10 Kraus Robert A Device for making artificial snow
US5004351A (en) * 1988-04-18 1991-04-02 Minnesota Mining & Manufacturing Company Reaction injection molding machine
US4952224A (en) * 1989-04-17 1990-08-28 Canadian Oxygen Limited Method and apparatus for cryogenic crystallization of fats
US5011293A (en) * 1989-10-12 1991-04-30 The United States Of America As Represented By The Secretary Of The Army Emulsifier mixing cell
US5074671A (en) * 1990-11-13 1991-12-24 Dew Engineering And Development Limited Mixing apparatus

Also Published As

Publication number Publication date
US5314506A (en) 1994-05-24
JP3282731B2 (ja) 2002-05-20
ES2078447T3 (es) 1995-12-16
CA2044706A1 (en) 1991-12-16
EP0461930B1 (de) 1995-09-13
DE69112917T2 (de) 1996-05-15
CA2044706C (en) 2003-02-25
JPH04231960A (ja) 1992-08-20
EP0461930A1 (de) 1991-12-18
IE67187B1 (en) 1996-03-06
IE912044A1 (en) 1991-12-18

Similar Documents

Publication Publication Date Title
DE69112917D1 (de) Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
FI893980A0 (fi) Akirala fluorhaltiga vaetskeformiga kristaller.
DE3879287D1 (de) Fvk-blatt und sein herstellungsverfahren.
NO171268C (no) Flytendekrystall-blanding
DE3865628D1 (de) Einrichtung zur zuechtung von kristallen.
DE68919431D1 (de) Schaltung zur Verbesserung der Bildqualität.
FI91840C (fi) Ennalleen saatettava tuote
DE69005925D1 (de) Flüssigkristallzusammensetzung.
DK472584A (da) Mikroindkapslet medikament i konfekturematrix
DE69125803D1 (de) Melassehaltiges maltitolkristall und herstellung desselben
FI900053A0 (fi) Flerfaergad bildruta.
NO880519L (no) Krympetang med skralle.
FI893474A7 (fi) Neutrofiler aktiverande faktor.
DE3876391D1 (de) Fluessigkristallfernsehen.
DE3784017D1 (de) Fluessigkristallzusammensetzung.
DE69117677D1 (de) Schaltung zur Verbesserung der Bildqualität
DE3871385D1 (de) Fluessigkristallzubereitung.
DE69128611D1 (de) Thiole enthaltende flüssigkristalle
DE68926839D1 (de) Flüssigkristallfernsehen
IT8421421A0 (it) Perfezionamenti in o relativi adispositivi di visualizzazione.
FR2619694B1 (fr) Presentoir utilisable pour le transport des vegetaux
DE69231552D1 (de) Komplex Kristall
DE69016317D1 (de) Einkristallziehungsapparat.
FI932343A7 (fi) Televisiojärjestelmään kohdistuva parannus
DE69112999D1 (de) Kristallisationsverfahren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee